Telix sees more backing for LAT1
TLX101 follows Ipax-1 with an apparent success in an academic trial.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.